ghk-cu clinical study skin GHK-Cu: The Peptide That Transforms and Tissue Health – Calibrate IV Enhanced Products

Highlights Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release Vancouver, British Columbia--(Newsfile Corp

Sixteen patients were contacted to review their knee pain symptom improvements 6 months to 1 year after receiving the injections

Peptide legality varies by country and can change, so researchers should verify current regulations in their jurisdiction

Falla, T